Intellia Raises $70m To Sharpen CRISPR Scissors
This article was originally published in Scrip
Executive Summary
Intellia Therapeutics raised a $70m Series B venture capital round that the Cambridge, Massachusetts-based company will use to sharpen its approach to CRISPR/Cas9, a pair of molecular scissors used to edit genes involved in hard-to-treat diseases.